Long-term reduction in peripheral blood HIV type 1 reservoirs following reduced-intensity conditioning allogeneic stem cell transplantation

Journal of Infectious Diseases

Volumn 207, Issue 11, 2013, Pages 1694-1702

  Henrich, Timothy J ^a,b   Hu, Zixin ^a,b   Li, Jonathan Z ^a,b   Sciaranghella, Gaia ^c   Busch, Michael P ^f,g   Keating, Sheila M ^f,g   Gallien, Sebastien ^a,h   Lin, Nina H ^b,d   Giguel, Francoise F ^d   Lavoie, Laura ^d   Ho, Vincent T ^b,e   Armand, Philippe ^b,e   Soiffer, Robert J ^b,e   Sagar, Manish ^a,b   Lacasce, Ann S ^b,e   Kuritzkes, Daniel R ^a,b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

^e DANA FARBER CANCER INSTITUTE   (United States)

^f BLOOD SYSTEMS RESEARCH INSTITUTE   (United States)

^g UNIVERSITY OF CALIFORNIA   (United States)

^h SAINT LOUIS HOSPITAL   (France)

Author keywords

CCR5; hematopoietic stem cell transplantation; HIV 1; HIV 1 persistence; reduced intensity allogeneic stem cell transplantation; viral reservoirs

Indexed keywords

ABACAVIR; BLEOMYCIN; BUSULFAN; CARBOPLATIN; CYCLOPHOSPHAMIDE; DACARBAZINE; DOXORUBICIN; EFAVIRENZ; EMTRICITABINE; ETOPOSIDE; FLUDARABINE; GEMCITABINE; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; IFOSFAMIDE; METHOTREXATE; NAVELBINE; NELFINAVIR; PREDNISONE; RALTEGRAVIR; RAPAMYCIN; RITUXIMAB; TACROLIMUS; TENOFOVIR; VINBLASTINE; VINCRISTINE; VIRUS DNA;

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANEMIA; ANTIBODY RESPONSE; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CASE REPORT; CCR5 GENE; CD4 LYMPHOCYTE COUNT; CD4+ T LYMPHOCYTE; CLINICAL FEATURE; DRUG EFFICACY; GENE; GENE MUTATION; GENOTYPE; GRAFT VERSUS HOST REACTION; HETEROZYGOSITY; HODGKIN DISEASE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LARGE CELL LYMPHOMA; MALE; MYELODYSPLASTIC SYNDROME; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; SALVAGE THERAPY; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE;

ANTI-RETROVIRAL AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; GENE DELETION; HETEROZYGOTE; HIV INFECTIONS; HIV-1; HUMANS; MALE; RECEPTORS, CCR5; RECEPTORS, HIV; STEM CELL TRANSPLANTATION; TRANSPLANTATION, HOMOLOGOUS; VIRAL LOAD;

EID: 84877278315     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/jit086     Document Type: Article

References (43)

1. Margolis DM. Histone deacetylase inhibitors and HIV latency. Curr Opin HIVAIDS 2011; 6:25-9.
2. Siliciano RF. What do we need to do to cure HIV infection. Top HIV Med 2010; 18:104-8.
3. Allers K, Hutter G, Hofmann J, et al. Evidence for the cure of HIV infection by CCR5{Delta}32/{Delta}32 stem cell transplantation. Blood 2010; 117:2791-9.
4. Hutter G, Nowak D, Mossner M, et al. Long-term control of HIV by CCR5 Delta32/Delta32 stem-cell transplantation. N Engl J Med 2009; 360:692-8.
5. Yukl SA, Chun T, Strain MC, et al. Challenges inherent in detecting HIV persistence during potentially curative interventions. Antiviral Therapy 2012; 17:A47.
6. Simonelli C, Zanussi S, Pratesi C, et al. Immune recovery after autologous stem cell transplantation is not different for HIV-infected versus HIV-uninfected patients with relapsed or refractory lymphoma. Clin Infect Dis 2010; 50:1672-9.
7. Cillo A, Krishnan A, Mitsuyasu R, et al. Plasma viremia and cellular HIV-1 DNA persist despite autologous hematopoietic stem cell transplantation for AIDS-related lymphoma [paper 154]. In: 19th Conference on Retroviruses and Opportunistic Infections, Seattle, WA, March 5-8 2012.
8. Cillo A, Krishnan A, Mitzuyasu R, et al. Plasma viremia and cellular HIV-1 DNA persist despite autologous hematopoietic stem cell transplantation for AIDS-related lymphoma. In: Fifth International Workshop of HIV Persistence During Therapy, St Maarten, West Indies December 6-9 2011.
9. Gabarre J, Marcelin AG, Azar N, et al. High-dose therapy plus autologous hematopoietic stem cell transplantation for human immunodeficiency virus (HIV)-related lymphoma: results and impact on HIV disease. Haematologica 2004; 89:1100-8.
10. Holland HK, Saral R, Rossi JJ, et al. Allogeneic bone marrow transplantation, zidovudine, and human immunodeficiency virus type 1 (HIV-1) infection. Studies in a patient with non-Hodgkin lymphoma. Ann Intern Med 1989; 111:973-81.
11. Contu L, La Nasa G, Arras M, et al. Allogeneic bone marrow transplantation combined with multiple anti-HIV-1 treatment in a case of AIDS. Bone Marrow Transplant 1993; 12:669-71.
12. Avettand-Fenoel V, Mahlaoui N, Chaix ML, et al. Failure of bone marrow transplantation to eradicate HIV reservoir despite efficient HAART. AIDS 2007; 21:776-7.
13. Huzicka I. Could bone marrow transplantation cure AIDS? Medical Hypotheses 1999; 52:247-57.
14. Woolfrey AE, Malhotra U, Harrington RD, et al. Generation of HIV-1-specific CD8+ cell responses following allogeneic hematopoietic cell transplantation. Blood 2008; 112:3484-7.
15. Sharkey M, Babic DZ, Greenough T, Gulick R, Kuritzkes DR, Stevenson M. Episomal viral cDNAs identify a reservoir that fuels viral rebound after treatment interruption and that contributes to treatment failure. PLoS Pathog 2011; 7:e1001303.
16. Malnati MS, Scarlatti G, Gatto F, et al. A universal real-time PCR assay for the quantification of group-M HIV-1 proviral load. Nat Protoc 2008; 3:1240-8.
17. Butler SL, Johnson EP, Bushman FD. Human immunodeficiency virus cDNA metabolism: notable stability of two-long terminal repeat circles. J Virol 2002; 76:3739-47.
18. Palmer BE, Boritz E, Wilson CC. Effects of sustained HIV-1 plasma viremia on HIV-1 Gag-specific CD4(+) T cell maturation and function. J Immunol 2004; 172:3337-47.
19. Palmer S, Maldarelli F, Wiegand A, et al. Low-level viremia persists for at least 7 years in patients on suppressive antiretroviral therapy. Proc Natl Acad Sci USA 2008; 105:3879-84.
20. Chun TW, Justement JS, Moir S, et al. Decay of the HIV reservoir in patients receiving antiretroviral therapy for extended periods: implications for eradication of virus. J Infect Dis 2007; 195:1762-4.
21. Chun TW, Justement JS, Murray D, et al. Rebound of plasma viremia following cessation of antiretroviral therapy despite profoundly low levels of HIV reservoir: implications for eradication. AIDS 2010; 24:2803-8.
22. Henrich TJ, Tsibris AM, Lewine NR, et al. Evolution of CCR5 antagonist resistance in an HIV-1 subtype C clinical isolate. J Acquir Immune Defic Syndr 2010; 55:420-7.
23. Lin NH, Negusse DM, Beroukhim R, et al. The design and validation of a novel phenotypic assay to determine HIV-1 coreceptor usage of clinical isolates. J Virol Methods 2010; 169:39-46.
24. Duong YT, Qiu M, De AK, et al. Detection of recent HIV-1 infection using a new limiting-antigen avidity assay: potential for HIV-1 incidence estimates and avidity maturation studies. PLoS One 2012; 7: e33328.
25. Gunthard HF, Frost SD, Leigh-Brown AJ, et al. Evolution of envelope sequences of human immunodeficiency virus type 1 in cellular reservoirs in the setting of potent antiviral therapy. J Virol 1999; 73:9404-12.
26. Martinez MA, Cabana M, Ibanez A, Clotet B, Arno A, Ruiz L. Human immunodeficiency virus type 1 genetic evolution in patients with prolonged suppression of plasma viremia. Virology 1999; 256:180-7.
27. Gandhi RT, Bosch RJ, Aga E, et al. No evidence for decay of the latent reservoir in HIV-1-infected patients receiving intensive enfuvirtidecontaining antiretroviral therapy. J Infect Dis 2010; 201:293-6.
28. Siliciano JD, Kajdas J, Finzi D, et al. Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4(+) T cells. Nat Med 2003; 9:727-8.
29. Huang Y, Paxton WA, Wolinsky SM, et al. The role of a mutant CCR5 allele in HIV-1 transmission and disease progression. Nat Med 1996; 2:1240-3.
30. Dean M, Carrington M, Winkler C, et al. Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene. Hemophilia Growth and Development Study, Multicenter AIDS Cohort Study, Multicenter Hemophilia Cohort Study, San Francisco City Cohort, ALIVE Study. Science 1996; 273: 1856-62.
31. Stewart GJ, Ashton LJ, Biti RA, et al. Increased frequency of CCR-5 delta 32 heterozygotes among long-term non-progressors with HIV-1 infection. The Australian Long-Term Non-Progressor Study Group. Aids 1997; 11:1833-8.
32. de Roda Husman AM, Koot M, Cornelissen M, et al. Association between CCR5 genotype and the clinical course of HIV-1 infection. Ann Intern Med 1997; 127:882-90.
33. Irie E, Shirota Y, Suzuki C, et al. Severe hypogammaglobulinemia persisting for 6 years after treatment with rituximab combined chemotherapy due to arrest of B lymphocyte differentiation together with alteration of T lymphocyte homeostasis. Int J Hematol 2010; 91:501-8.
34. Sarantopoulos S, Stevenson KE, Kim HT, et al. Altered B-cell homeostasis and excess BAFF in human chronic graft-versus-host disease. Blood 2009; 113:3865-74.
35. Nordoy T, Husebekk A, Aaberge IS, et al. Humoral immunity to viral and bacterial antigens in lymphoma patients 4-10 years after high-dose therapy with ABMT. Serological responses to revaccinations according to EBMT guidelines. Bone Marrow Transplant 2001; 28:681-7.
36. Ljungman P, Duraj V, Magnius L. Response to immunization against polio after allogeneic marrow transplantation. Bone Marrow Transplant 1991; 7:89-93.
37. Knoll A, Boehm S, Hahn J, Holler E, Jilg W. Reactivation of resolved hepatitis B virus infection after allogeneic haematopoietic stem cell transplantation. Bone Marrow Transplant 2004; 33:925-9.
38. Hatano H, Delwart EL, Norris PJ, et al. Evidence of persistent low-level viremia in long-term HAART-suppressed, HIV-infected individuals. AIDS 2010; 24:2535-9.
39. Killian MS, Norris PJ, Rawal BD, et al. The effects of early antiretroviral therapy and its discontinuation on the HIV-specific antibody response. AIDS Res Hum Retroviruses 2006; 22:640-7.
40. Pereyra F, Addo MM, Kaufmann DE, et al. Genetic and immunologic heterogeneity among persons who control HIV infection in the absence of therapy. J Infect Dis 2008; 197:563-71.
41. Lambotte O, Ferrari G, Moog C, et al. Heterogeneous neutralizing antibody and antibody-dependent cell cytotoxicity responses in HIV-1 elite controllers. AIDS 2009; 23:897-906.
42. Bailey JR, Lassen KG, Yang HC, et al. Neutralizing antibodies do not mediate suppression of human immunodeficiency virus type 1 in elite suppressors or selection of plasma virus variants in patients on highly active antiretroviral therapy. J Virol 2006; 80:4758-70.
43. Siliciano JD, Siliciano RF. Enhanced culture assay for detection and quantitation of latently infected, resting CD4+ T-cells carrying replication-competent virus in HIV-1-infected individuals. Methods Mol Biol 2005; 304:3-15.